Skip to main content

Table 2 Clinical characteristics, treatment and comorbidities of 14 nonsurvivors with COVID-19

From: Clinical characteristics of 14 COVID-19 deaths in Tianmen, China: a single-center retrospective study

Symptoms

Nonsurvivors (n = 14)

Fever

11 (78.6%)

Cough

12 (85.7%)

Sputum production

4 (28.6%)

Dyspnea

10 (71.4%)

Myalgia

0

Chest tightness

2 (14.3%)

Headache

1 (7.1%)

Diarrhea

4 (28.6%)

Blood pressure

 Systolic, mm Hg

133.5 (16.0)

 Diastolic, mm Hg

78.1 (10.7)

Laboratory resultsa

 Leukocytes (3.5–9.5), ×  109/L,

9.9 (3.0)

 Lymphocyte count (1.1–3.2), × 109/L,

0.6 (0.3)

 Neutrophils (1.8–6.3), × 109/L

9.2 (2.9)

 C-reactive protein (≤6.0), × 109/L

156.8 (75.5)

Treatment

 High-flow nasal cannula

14 (100%)

 Mechanical ventilation

  Noninvasive

9 (64.3%)

  Invasive

3 (21.4%)

 Antiviral agents

14 (100%)

 Antibacterial agents

13 (92.9%)

 Antifungal agents

1 (7.1%)

 Glucocorticoids

10 (71.4%)

 Immunoglobulin

5 (35.7%)

 α-IFN

4 (28.6%)

 Renal replacement therapy

4 (28.6%)

Comorbidities

 Acute respiratory distress syndrome

13 (92.9%)

 Acute kidney injury

3 (21.4%)

 Liver dysfunction

3 (21.4%)

 Cardiac injury

4 (28.6%)

 Hyperglycemia

1 (7.1%)

 Multiple organ dysfunction syndrome

2 (14.3%)

 Bacteremia

2 (14.3%)

 Fungal septicemia

1 (7.1%)

  1. Data are shown as n (%) or mean (SD)
  2. aOne patient had incomplete data, n = 13